Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compstatins: the dawn of clinical C3-targeted complement inhibition

25 Jan 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Complement system in diseases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35090732
DOI: 10.1016/j.tips.2022.01.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compstatins: the dawn of clinical C3-targeted complement inhibitionPMID 35090732Read ↗

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside interventionSemantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

Complement‐targeted therapeutics: Are we there yet, or just getting started?Semantic proximity Read ↗

Therapeutic targeting of the complement systemSemantic proximity Read ↗

Complement in human disease: approved and up-and-coming therapeuticsSemantic proximity Read ↗

First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunitiesSemantic proximity Read ↗

Complement‐targeted therapeutics: An emerging field enabled by academic drug discoverySemantic proximity Read ↗

Developments in anti-complement therapy; from disease to clinical trialSemantic proximity Read ↗

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsSemantic proximity Read ↗

Complement in therapy and diseaseSemantic proximity Read ↗

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacySemantic proximity Read ↗

Clinical promise of next-generation complement therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.